An Experimental Treatment for Adenoid Cystic Carcinoma Earns Orphan Drug Designation

According to a story from apnews.com, the drug developer Ayala Pharmaceuticals has recently announced that the company's investigational product candidate, known as as AL101, has earned Orphan Drug Designation. This…

Continue Reading An Experimental Treatment for Adenoid Cystic Carcinoma Earns Orphan Drug Designation
The Orphan Drug Designation for the Drug Dovitinib Has Been Transferred to a New Company
Source: Pixabay

The Orphan Drug Designation for the Drug Dovitinib Has Been Transferred to a New Company

The Orphan Drug Designation awarded to the drug dovitinib for treating adenoid cystic carcinoma has been transferred from Novartis to Oncology Venture. The full article can be found here, at…

Continue Reading The Orphan Drug Designation for the Drug Dovitinib Has Been Transferred to a New Company
Investigational Treatment for Adenoid Cystic Carcinoma Gets Orphan Drug Designation Under New Developer
Source: Pixabay

Investigational Treatment for Adenoid Cystic Carcinoma Gets Orphan Drug Designation Under New Developer

According to a story from inpublic.globenewswire.com, the U.S. Food and Drug Administration has recently transferred its Orphan Drug designation for dovitinib from to Oncology Venture (OV) from Novartis, according to…

Continue Reading Investigational Treatment for Adenoid Cystic Carcinoma Gets Orphan Drug Designation Under New Developer
Experimental New Drug Offers Hope for Rare Salivary Gland Cancer
Source: Pixabay

Experimental New Drug Offers Hope for Rare Salivary Gland Cancer

Another great breakthrough in research science! A new study found that an experimental drug combined with the traditional chemotherapy drug cisplatin successfully eliminated a rare salivary gland tumor and prevented a recurrence…

Continue Reading Experimental New Drug Offers Hope for Rare Salivary Gland Cancer
Close Menu